Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State

Cancer Research
Masoud H Manjili

Abstract

Species evolve by mutations and epigenetic changes acting on individuals in a population; tumors evolve by similar mechanisms at a cellular level in a tissue. This article reviews growing evidence about tumor dormancy and suggests that (i) cellular malignancy is a natural byproduct of evolutionary mechanisms, such as gene mutations and epigenetic modifications, which is manifested in the form of tumor dormancy in healthy individuals as well as in cancer survivors; (ii) cancer metastasis could be an early dissemination event that could occur during malignant dormancy even before primary cancer is clinically detectable; and (iii) chronic inflammation is a key factor in awakening dormant malignant cells at the primary site, leading to primary cancer development, and at distant sites, leading to advanced stage diseases. On the basis of this evidence, it is reasonable to propose that we are all cancer survivors rather than cancer-free individuals because of harboring dormant malignant cells in our organs. A better understanding of local and metastatic tumor dormancy could lead to novel cancer therapeutics for the prevention of cancer. Cancer Res; 77(10); 2564-9. ©2017 AACR.

References

Jan 16, 1999·Journal of the National Cancer Institute·T G KarrisonP Meier
Jul 5, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Patrick E FieldsRichard A Flavell
Jan 8, 2003·Seminars in Oncology·Judah Folkman
Jun 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Oleg Schmidt-KittlerChristoph A Klein
Feb 27, 2004·Nature·Judah Folkman, Raghu Kalluri
Mar 23, 2004·Annual Review of Immunology·Gavin P DunnRobert D Schreiber
Dec 23, 2004·Seminars in Cancer Biology·Jarle Breivik
Apr 25, 2006·Current Biology : CB·Masamitsu FukuyamaJoel H Rothman
Oct 10, 2006·Future Oncology·Benjamin D HedleyAnn F Chambers
Feb 22, 2007·Journal of the National Cancer Institute·Kevin T NashDanny R Welch
Oct 25, 2007·Nature Reviews. Cancer·Julio A Aguirre-Ghiso
Mar 7, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kristian HallermalmJelena Levitskaya
Jun 3, 2008·Journal of Leukocyte Biology·Michele W L TengMark J Smyth
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven W Cole
Dec 17, 2009·International Journal of Radiation Oncology, Biology, Physics·Atsushi Jinno-OueHiroo Hoshino
May 27, 2010·The Journal of Clinical Investigation·Jo EylesJean-Pierre Abastado
Mar 2, 2011·Immunology and Cell Biology·Sarat K DalaiScheherazade Sadegh-Nasseri
Jan 24, 2012·Cell·Andrew D RhimBen Z Stanger
Feb 18, 2014·Cancer Research·Irene RomeroAngel M Garcia-Lora
Aug 15, 2014·Nature Reviews. Cancer·María Soledad SosaJulio A Aguirre-Ghiso
Nov 21, 2014·Cancer Research·Masoud H Manjili
Jan 13, 2015·Scientific Reports·Yuka MatsudaMakoto Yamagishi
Mar 25, 2015·Nature Reviews. Cancer·Cyrus M Ghajar
Aug 11, 2015·Journal of Advanced Research·Nicholas PavlidisRabab Gaafar
Aug 14, 2015·Cancer Research·Russell HughesClaire E Lewis
Jan 13, 2016·Malaria Journal·Bronner P GonçalvesBridget S Penman
Feb 13, 2016·Cell·Roberta ScognamiglioAndreas Trumpp
Jun 15, 2016·The Journal of Experimental Medicine·Joanne H ReedChristopher C Goodnow
Jul 6, 2016·EBioMedicine·Lynnette Fernandez-CuestaPaul Brennan
Jul 28, 2016·Tuberculosis·S LipworthS H Gillespie

❮ Previous
Next ❯

Citations

Dec 22, 2017·F1000Research·Laura Vera-Ramirez, Kent W Hunter
Jun 7, 2018·Cancer Biotherapy & Radiopharmaceuticals·Yongxin LinChangjun Wang
Oct 3, 2018·PLoS Biology·Frédéric ThomasBeata Ujvari
Sep 15, 2019·Nature Reviews. Cancer·Christine A Iacobuzio-DonahueTravis J Hollman
Jan 4, 2019·Journal of Biological Engineering·Shantanu PradhanJohn H Slater
Mar 14, 2020·Cellular Oncology (Dordrecht)·Leticia Serrano-OviedoEva María Galán-Moya
Feb 23, 2018·Journal of Leukocyte Biology·Hussein F AqbiMasoud H Manjili
Aug 23, 2019·Cancers·Rana Jahanban-EsfahlanPeyman Zare
Apr 5, 2018·Frontiers in Oncology·Amit S YadavDhiraj Kumar
Nov 21, 2018·Frontiers in Oncology·Xiao YangYaling Tang
May 31, 2019·Frontiers in Oncology·Kağan Dökümcü, Ramin M Farahani
Feb 8, 2020·Cells·Francisco Triana-MartínezEduardo Domínguez
Aug 25, 2020·International Journal of Environmental Research·Walter Gottlieb Land
Jan 17, 2020·Journal of Cellular Biochemistry·Chunjue YuanYunbao Pan
Jun 20, 2020·Cellular and Molecular Life Sciences : CMLS·Wenhui HuShiwu Dong
Nov 16, 2020·The FEBS Journal·Maartje P F DamenColinda L G J Scheele
Mar 22, 2019·Cancer Research·Arseniy E Yuzhalin
Feb 14, 2018·Cancer Research·Mario GiulianoMeghana V Trivedi
Jul 1, 2019·Trends in Immunology·Simone L ParkLaura K Mackay
Nov 3, 2020·Journal of the Egyptian National Cancer Institute·Leonardo MuratoriGiorgio Vittorio Scagliotti
Nov 17, 2020·Frontiers in Immunology·Antonella SistiguRuggero De Maria
Mar 28, 2021·Cancer Cell International·Li DaiXin-Hua Liang
Apr 1, 2021·Seminars in Cancer Biology·Saeed H ManjiliMasoud H Manjili
Nov 12, 2018·Biochemical Pharmacology·François M ValletteDominique Heymann
May 1, 2021·Advanced Healthcare Materials·Cindy J Farino ReyesJohn H Slater
Jun 3, 2021·International Journal of Molecular Sciences·Georgia GomatouElias A Kotteas
Jun 13, 2021·Molecular Cancer·Dongwei ZhuShengjun Wang
Sep 12, 2021·Nature Reviews. Cancer·Anabel EckerlingShamgar Ben-Eliyahu
Sep 15, 2021·The Biochemical Journal·Jocelyn F Chen, Qin Yan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

© 2022 Meta ULC. All rights reserved